127 related articles for article (PubMed ID: 38518506)
1. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?
Immovilli P; Schiavetti I; Franceschini A; De Mitri P; Gelati L; Rota E; Guidetti D
Mult Scler Relat Disord; 2024 May; 85():105547. PubMed ID: 38518506
[TBL] [Abstract][Full Text] [Related]
2. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
[TBL] [Abstract][Full Text] [Related]
3. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
Spierer R; Lavi I; Bloch S; Mazar M; Golan D
J Neurol; 2023 Oct; 270(10):4632-4639. PubMed ID: 37589743
[TBL] [Abstract][Full Text] [Related]
4. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
Wu X; Wang L; Shen L; Tang K
EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
[TBL] [Abstract][Full Text] [Related]
5. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
[TBL] [Abstract][Full Text] [Related]
6. Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
Etemadifar M; Abhari AP; Nouri H; Eighani N; Salari M; Sedaghat N
J Neurol Sci; 2023 Jan; 444():120518. PubMed ID: 36521195
[TBL] [Abstract][Full Text] [Related]
7. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience.
Bertozzi A; Mariottini A; Marchi L; Cristinzi MD; Nistri R; Damato V; Mechi C; Barilaro A; Massacesi L; Repice AM
Mult Scler Relat Disord; 2023 Apr; 72():104582. PubMed ID: 36889098
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
Klineova S; Farber RS; DeAngelis T; Leung T; Smith T; Blanck R; Zhovtis-Ryerson L; Harel A
Mult Scler; 2023 Jul; 29(8):990-1000. PubMed ID: 37431628
[TBL] [Abstract][Full Text] [Related]
10. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
Sormani MP; Schiavetti I; Inglese M; Carmisciano L; Laroni A; Lapucci C; Visconti V; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Cocco E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Pizzorno M; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2022 Jun; 80():104042. PubMed ID: 35526306
[TBL] [Abstract][Full Text] [Related]
12. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
Schiavetti I; Cordioli C; Stromillo ML; Teresa Ferrò M; Laroni A; Cocco E; Cola G; Pasquali L; Rilla MT; Signoriello E; Iodice R; Di Sapio A; Lanzillo R; Caleri F; Annovazzi P; Conte A; Liberatore G; Ruscica F; Docimo R; Bonavita S; Ulivelli M; Cavalla P; Patti F; Ferraro D; Clerico M; Immovilli P; Di Filippo M; Salvetti M; Sormani MP
Mult Scler; 2022 Nov; 28(13):2106-2111. PubMed ID: 35735030
[TBL] [Abstract][Full Text] [Related]
15. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
[TBL] [Abstract][Full Text] [Related]
16. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
17. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
Etemadifar M; Nouri H; Pitzalis M; Idda ML; Salari M; Baratian M; Mahdavi S; Abhari AP; Sedaghat N
J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):986-994. PubMed ID: 35688629
[TBL] [Abstract][Full Text] [Related]
20. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
